July 17, 2007
New Boston Scientific stent mends broken hearts
By Cory Hopkins
A new stent designed by Natick-based Boston Scientific Corp., intended to buttress clogged arteries at the point where they diverge into smaller vessels, was successfully implanted in a New Zealand patient recently.
The company said the procedure involving the first human implementation of its TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System was successfully performed by Dr. John Ormiston at Auckland City Hospital in Auckland, New Zealand.
As much as 30 percent of coronary artery disease occurs at an arterial bifurcation, where one larger artery diverges into two, the company said. It is difficult to treat these points in arteries with traditional tubular stents, according to the company.
The TAXUS Petal Stent consists of a traditional drug-eluting stent with a side structure (the Petal Strut) in the middle of the stent that opens into the side branch.
The procedure marked the beginning of the TAXUS Petal I first human use trial. The trial will enroll 45 patients in New Zealand, France and Germany in anticipation of starting a wider domestic and international trial upon its successful completion, the company said.
"Bifurcations are a major challenge in interventional cardiology," said Dr. Ormiston. "The development of a dedicated drug-eluting bifurcation stent is an important advancement."
The company said the procedure involving the first human implementation of its TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System was successfully performed by Dr. John Ormiston at Auckland City Hospital in Auckland, New Zealand.
As much as 30 percent of coronary artery disease occurs at an arterial bifurcation, where one larger artery diverges into two, the company said. It is difficult to treat these points in arteries with traditional tubular stents, according to the company.
The TAXUS Petal Stent consists of a traditional drug-eluting stent with a side structure (the Petal Strut) in the middle of the stent that opens into the side branch.
The procedure marked the beginning of the TAXUS Petal I first human use trial. The trial will enroll 45 patients in New Zealand, France and Germany in anticipation of starting a wider domestic and international trial upon its successful completion, the company said.
"Bifurcations are a major challenge in interventional cardiology," said Dr. Ormiston. "The development of a dedicated drug-eluting bifurcation stent is an important advancement."
WBJ Web Partners
Most Recent
Most Recent
0 Comments